Ubs Group Ag Rubius Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
BUY
$0.14 - $0.31 $8,494 - $18,809
60,676 Added 506.22%
72,662 $13,000
Q3 2022

Nov 10, 2022
BUY
$0.46 - $1.29 $5,513 - $15,461
11,986 New
11,986 $5,000
Q2 2022

Aug 10, 2022
SELL
$0.79 - $5.98 $412 - $3,121
-522 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$4.25 - $10.4 $449,148 - $1.1 Million
-105,682 Reduced 99.51%
522 $3,000
Q4 2021

Feb 14, 2022
BUY
$9.68 - $17.74 $239,425 - $438,781
24,734 Added 30.36%
106,204 $1.03 Million
Q3 2021

Nov 15, 2021
BUY
$17.6 - $25.91 $1.26 Million - $1.86 Million
71,837 Added 745.74%
81,470 $1.46 Million
Q2 2021

Aug 13, 2021
SELL
$22.26 - $28.43 $32,900 - $42,019
-1,478 Reduced 13.3%
9,633 $235,000
Q1 2021

May 12, 2021
BUY
$8.02 - $32.01 $66,012 - $263,474
8,231 Added 285.8%
11,111 $294,000
Q4 2020

Feb 11, 2021
BUY
$4.23 - $8.73 $7,952 - $16,412
1,880 Added 188.0%
2,880 $22,000
Q3 2020

Nov 12, 2020
SELL
$4.65 - $6.25 $5,989 - $8,050
-1,288 Reduced 56.29%
1,000 $5,000
Q2 2020

Jul 31, 2020
SELL
$4.01 - $6.88 $41,808 - $71,730
-10,426 Reduced 82.0%
2,288 $14,000
Q1 2020

May 01, 2020
SELL
$3.74 - $9.84 $91,659 - $241,158
-24,508 Reduced 65.84%
12,714 $56,000
Q4 2019

Feb 14, 2020
BUY
$7.23 - $14.12 $197,097 - $384,925
27,261 Added 273.68%
37,222 $354,000
Q3 2019

Nov 14, 2019
BUY
$7.85 - $15.75 $78,193 - $156,885
9,961 New
9,961 $78,000
Q2 2019

Aug 14, 2019
SELL
$13.5 - $19.94 $310 - $458
-23 Closed
0 $0
Q1 2019

May 14, 2019
BUY
$13.27 - $18.51 $305 - $425
23 New
23 $0
Q4 2018

Feb 14, 2019
SELL
$13.83 - $22.97 $39,664 - $65,877
-2,868 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$20.06 - $26.94 $57,532 - $77,263
2,868 New
2,868 $69,000

Others Institutions Holding RUBY

# of Institutions
2
Shares Held
325
Call Options Held
0
Put Options Held
0
View Full List

About Rubius Therapeutics, Inc.

RUBY Quotes by TradingView
  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email